Three of the most respected names in biomedical research have joined forces right here in the Boston area to take on some of medicine’s most difficult challenges. The Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory have officially launched the Center for Therapeutic Genetics — a new nonprofit initiative dedicated to developing genetic medicines for patients living with rare and ultra-rare diseases.
The collaboration brings together world-class expertise in genomics, pediatric medicine, and genetic research under one shared mission: to create treatments for conditions that have long gone without adequate medical options. Rare and ultra-rare diseases often affect small numbers of patients, making them difficult targets for traditional pharmaceutical development. By forming a nonprofit center, the three institutions signal a commitment to putting patients first, even when commercial incentives may be limited.
The Broad Institute, headquartered in Cambridge, is globally recognized for its pioneering work in genomics and gene editing. Boston Children’s Hospital is consistently ranked among the top pediatric hospitals in the nation, making it an ideal partner for addressing diseases that frequently affect children. The Jackson Laboratory, a renowned nonprofit biomedical research institution, rounds out the team with deep expertise in mammalian genetics and personalized medicine.
Together, these organizations represent a powerhouse of scientific talent and institutional knowledge. The Center for Therapeutic Genetics is positioned to accelerate the development of genetic medicines by pooling resources, data, and research capabilities that might otherwise remain siloed across separate institutions.
For Boston-area families touched by rare genetic conditions, the launch of this center is a meaningful and hopeful development. It reflects the region’s long-standing reputation as a global hub for life sciences innovation — and demonstrates that some of its most prestigious institutions are willing to collaborate in pursuit of breakthroughs that could change lives. With the center now officially open, the research community and patient advocates alike will be watching closely as this promising partnership gets to work.
